LYBHIGH SIGNALFINANCIAL10-K

LyondellBasell experienced a substantial deterioration in financial performance with revenue declining 25% alongside significantly higher interest expenses and reduced profitability.

The company faces a challenging operating environment with weakened demand conditions leading to lower sales volumes and pricing pressure. The substantial increase in debt levels and corresponding interest burden suggests either increased capital investment needs or potential financial stress, while the decline in working capital components indicates reduced business activity levels.

Comparing 2026-02-20 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

LyondellBasell's financial position deteriorated meaningfully with revenue falling 25% to $30.2B and net income declining 28% to $3.4B. Interest expense grew substantially while total debt increased 34% to $5.8B, creating additional financial burden. Operating cash flow dropped 41% to $2.3B, and both accounts receivable and inventory declined roughly 25%, reflecting the reduced scale of operations and suggesting weaker underlying demand conditions across the company's chemical and refining businesses.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+66.2%
$287.0M→$477.0M

Interest expense surged 66.2% — significant debt increase or rising rates materially impacting earnings.

Operating Cash Flow
Cash Flow
-40.8%
$3.8B→$2.3B

Operating cash flow fell 40.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Total Debt
Balance Sheet
+34.2%
$4.3B→$5.8B

Debt increased 34.2% — substantial leverage increase; assess whether deployed for growth or covering losses.

Net Income
P&L
-27.6%
$4.7B→$3.4B

Net income declined 27.6% — review whether driven by operations, interest costs, or non-recurring items.

Accounts Receivable
Balance Sheet
-25.7%
$4.6B→$3.4B

Receivables declined — improved collection efficiency or conservative revenue recognition.

Revenue
P&L
-25.2%
$40.3B→$30.2B

Revenue softened 25.2% — monitor whether this is cyclical or structural.

Inventory
Balance Sheet
-24.2%
$4.7B→$3.5B

Inventory reduced 24.2% — lean inventory management or demand outpacing supply.

Stockholders Equity
Balance Sheet
-19.1%
$12.5B→$10.1B

Equity decreased 19.1% — buybacks or losses reducing book value, monitor solvency ratios.

Current Assets
Balance Sheet
-11.4%
$12.3B→$10.9B

Current assets declined 11.4% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-02-20
PRIOR — 2025-02-27
ADDED
The registrant had 322,169,978 ordinary shares outstanding at February 18, 2026 (excluding 18,252,520 treasury shares).
We also develop and license chemical and polyolefin process technologies, and manufacture and sell polyolefin catalysts.
Our CLCS business is a part of our Olefins and Polyolefins-Americas and Olefins and Polyolefins-Europe, Asia, International segments.
Our strategy is supported by an experienced leadership team, an optimized organizational structure and an ownership mindset; our advantaged cost position and global scale; our robust Value Enhancement Program; our strong cash generation; and a capital allocation approach grounded in an investment grade balance sheet.
SEGMENTS We manage our operations through five operating segments.
+7 more — sign up free →
REMOVED
The registrant had 323,446,166 ordinary shares outstanding at February 25, 2025 (excluding 16,976,332 treasury shares).
Table of Conten ts Page Cautionary statement for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 2 PART I Items 1.
Our refining business consists of our Houston refinery, which processes crude oil into refined products such as gasoline and distillates.
We also develop and license chemical and polyolefin process technologies and manufacture and sell polyolefin catalysts.
In March 2023, we introduced our new strategy to deliver sustainable solutions and profitable long-term growth.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →